ArticleScientific reports2025
Novel quantitative valuation of hybrid perovskite solar cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
As an emerging photovoltaic technology, hybrid perovskite solar cells (PSCs) have achieved excellent performance through rapid development in recent years. High power conversion efficiency (PCE) and excellent stability further promote the commercialization of PSCs. To date, the perovskite light-harvesting active materials are diversified and the device fabrication process is also various. Considered the fabrication costs and steps of PSCs based on different active materials, the quantitative valuation of different hybrid PSCs with PCE above 20% is implemented using data envelopment analysis (DEA) for the first time. This valuation mainly focuses on the inputs (cost and fabrication steps) and outputs (PCE and stability). No weights are needed during the whole analytical process. This ensures the convenience and ease of operation of the analysis, promoting the universality of this method. The results show a detailed analysis of different PSCs from an economic perspective and develop a new way to evaluate PSCs. Meanwhile, the results and this novel valuation method will provide promising guidance for the commercialization of PSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.